[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053935":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":51,"collaborators":20,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Mahidol University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"study arm","EXPERIMENTAL","olanzapine palonosetron with dexamethasone on day 1 only",[13],"Drug: dexamethasone sparing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","dexamethasone sparing","omit dexamethasone on day 2-4",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Suthinee Ithimakin","CONTACT","+66898127440","aesi105@yahoo.co.th",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Faculty of Medicine Siriraj Hospital, Mahidol University","RECRUITING","Bangkok","10700","Thailand",{"type":35,"coordinates":36},"Point",[37,38],100.50144,13.75398,{"lat":38,"lon":37},[41,43,46,49],{"name":23,"role":24,"phone":42,"phoneExt":20,"email":26},"0898127440",{"name":44,"role":45,"phone":20,"phoneExt":20,"email":20},"Sirisopa Techawattanawanna, M.D","PRINCIPAL_INVESTIGATOR",{"name":47,"role":48,"phone":20,"phoneExt":20,"email":20},"Akarin Nimmannit, M.D","SUB_INVESTIGATOR",{"name":50,"role":48,"phone":20,"phoneExt":20,"email":20},"Visullaya Sa-nguanwongwan, M.D",{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100053935",false,"NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin","ALL","18 Years",{"count":62,"type":63},95,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[69,70,71,72],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[74,75,17,76],"cisplatin","chemotherapy induced nausea vomiting","olanzapine","2026-07-07",{"date":79,"type":80},"2026-07-13","ACTUAL",{"date":82,"type":80},"2026-02-10",{"date":84,"type":63},"2027-11-15",{"name":5,"class":6},1]